What’s in Therapix Biosciences Ltd. (TRPX) After Achieving 52-Week Low?

July 16, 2018 - By Vernon Prom

The stock of Therapix Biosciences Ltd. (NASDAQ:TRPX) hit a new 52-week low and has $2.90 target or 7.00 % below today’s $3.12 share price. The 9 months bearish chart indicates high risk for the $11.59 million company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $2.90 price target is reached, the company will be worth $811,370 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 1.58% or $0.05 during the last trading session, reaching $3.12. About 21,885 shares traded. Therapix Biosciences Ltd. (NASDAQ:TRPX) has declined 32.12% since July 16, 2017 and is downtrending. It has underperformed by 44.69% the S&P500.

Another recent and important Therapix Biosciences Ltd. (NASDAQ:TRPX) news was published by Nasdaq.com which published an article titled: “Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.” on July 11, 2018.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company has market cap of $11.59 million. The Company’s drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome ; and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. It currently has negative earnings. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid product for sleep disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.